Expanded Access: Past, Present and Future Improvements
Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Expanded access is a program that provides patients with investigational medicinal products (IMP) for treatment purposes. These patients are often excluded from clinical trials but could still benefit from access to the drugs, biologics or medical devices being tested. While, in concept, expanded access represents a way to help more patients receive new and developing treatments, in reality, the process is complex and often misunderstood.
Related Education Resources.
All Resources2018 GCSG US Conference Recap Video
Topic: Conference
Video
Members
PATIENT Receptivity to Direct-to-Patient Shipment in Clinical Trials - a GCSG sponsored study
Topic: Direct-to-Patient
White Paper
Members
The Exponential Growth of Decentralized Trials, Direct-to-Patient and the Future of the Clinical Trials Landscape in Europe
Topics: Conference, Regulatory
Executive Summary
Members
